Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 11/20 | 0.59 |
| ▸ | TP53 | P04637 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13376561 | 0.91 | LMNA (0.52) | LMNATP53MAPTPOLBTDP1 | |
| SCHEMBL2766128 | 0.91 | LMNA (0.51) | LMNATP53MAPTPOLBTDP1 | |
| SCHEMBL3285238 | 0.84 | TP53 (0.52) | LMNATP53MAPT | |
| SCHEMBL2766614 | 0.81 | TP53 (0.59) | LMNATP53MAPTPOLB | |
| SCHEMBL3290069 | 0.81 | LMNA (0.58) | LMNATP53MAPTPOLB | |
| SCHEMBL3290063 | 0.81 | LMNA (0.50) | LMNATP53POLB | |
| SCHEMBL2766277 | 0.80 | LMNA (0.43) | LMNATP53POLB | |
| SCHEMBL2767413 | 0.76 | TP53 (0.41) | LMNATP53MAPTPOLB | |
| SCHEMBL2766178 | 0.75 | LMNA (0.41) | LMNATP53MAPTPOLB | |
| SCHEMBL2765216 | 0.72 | LMNA (0.48) | LMNATP53MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1858890-B1 | NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-04-14 | — | — | EP | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | LMNA 1767/4885TP53 3318/4885MAPT 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.